GYRE (Gyre Therapeutics) EV-to-EBIT : 78.64 (As of Dec. 15, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gyre Therapeutics's Enterprise Value is $816.0 Mil. Gyre Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $10.4 Mil. Therefore, Gyre Therapeutics's EV-to-EBIT for today is 78.64.

The historical rank and industry rank for Gyre Therapeutics's EV-to-EBIT or its related term are showing as below:

GYRE' s EV-to-EBIT Range Over the Past 10 Years
Min: 20.27 Med: 74.36 Max: 152.69
Current: 78.64

During the past 3 years, the highest EV-to-EBIT of Gyre Therapeutics was 152.69. The lowest was 20.27. And the median was 74.36.

GYRE's EV-to-EBIT is ranked worse than
93.41% of 425 companies
in the Biotechnology industry
Industry Median: 9.74 vs GYRE: 78.64

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Gyre Therapeutics's Enterprise Value for the quarter that ended in Sep. 2024 was $1,087.5 Mil. Gyre Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $10.4 Mil. Gyre Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 0.95%.

Gyre Therapeutics EV-to-EBIT Historical Data

The historical data trend for Gyre Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics EV-to-EBIT Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-EBIT

102.24

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-EBIT	Get a 7-Day Free Trial					-	102.24	72.18	54.49	104.80

Competitive Comparison of Gyre Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Gyre Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's EV-to-EBIT falls into.

Gyre Therapeutics EV-to-EBIT Calculation

Gyre Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	816.045	/	10.377
	=	78.64

Gyre Therapeutics's current Enterprise Value is $816.0 Mil.
Gyre Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.4 Mil.

Gyre Therapeutics (NAS:GYRE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Gyre Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 )	=	EBIT	/	Enterprise Value (Q: Sep. 2024 )
	=	10.377	/	1087.54753
	=	0.95 %

Gyre Therapeutics's Enterprise Value for the quarter that ended in Sep. 2024 was $1,087.5 Mil.
Gyre Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.4 Mil.

Gyre Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.